In this respect, hCFPs, TRAIL fusion proteins and DR5-agonistic bispecific antibodies targeted at CSPG4 are highly promising candidates for the treatment of highly aggressive cancers with a high recurrence rate and poor prognosis. Here, TNFSF10 is linked to cancer.